Biliary tract cancer research focuses on chemoimmunotherapy combinations, FGFR2 and IDH1-directed targeted therapy, and molecular profiling of cholangiocarcinoma subtypes.
Final post hoc analysis of the global, double-blind, placebo-controlled phase 3 TOPAZ-1 trial (685 patients randomized 1:1) reporting the longest published follow-up — approximately 4 years — of an immunotherapy-plus-chemotherapy regimen in first-line advanced biliary tract cancer (aBTC)
Please enable JavaScript to access the latest cancer research articles and studies.